Study to Evaluate the Effect of the Coadministration of SCH 497079 (a Histamine 3 [H3] Receptor Antagonist) Plus Desloratadine on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis Who Have Been Exposed to Pollen in the Vienna Challenge Chamber (VCC)

Registry ID

EUCTR2004-001883-39

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Schering Plough Reserach Institute

Start date

2004-09-21

Completion date

2005-01-14

Last update

2026-08-16

Conditions

• Seasonal Allergic Rhinitis

Summary

The primary objective of this study is to evaluate the effect on nasal congestion of a maximally tolerated dose of SCH 497079, when taken in combination with DL 5 mg (identified in Phase 1 studies), in subjects with seasonal allergic rhinitis (SAR) who have been exposed to pollen in the VCC. This objective will be accomplished by comparison of the effect on nasal congestion, over the 7.5 hour observation period, of the coadministration of DL 5 mg and SCH 497079 100 mg with that of DL 5 mg taken alone.

Locations

• , , Austria

Related clinical trials

• Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study
• The Role of the Nasal Allergen Provocation Test in Starting and Monitoring Allergen Immunotherapy
• Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis
• Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis
• A Clinical Study on the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis
• Acupuncture at the Sphenopalatine Ganglion in the Treatment of Moderate-to-severe Seasonal Allergic Rhinitis

View on source registry